Yuan Liang, Jiang Xiuxing, Gong Qihai, Gao Ning
Key Laboratory of Basic Pharmacology of Ministry of Education, Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, Guizhou 563006, China.
College of Pharmacy, Army Medical University, 30 Gaotanyan Street, Shapingba District, Chongqing 400038, China.
Pharmacol Ther. 2023 Apr;244:108386. doi: 10.1016/j.pharmthera.2023.108386. Epub 2023 Mar 16.
Arsenic resistance protein 2 (Ars2) is a nuclear protein that plays a critical role in the regulation of microRNA (miRNA) biogenesis. Ars2 is required for cell proliferation and for the early stages of mammalian development through a possible effect on miRNA processing. Increasing evidence reveal that Ars2 is highly expressed in proliferating cancer cells, suggesting that Ars2 may be a potential therapeutic target for cancer. Therefore, development of the novel Ars2 inhibitors could represent the novel therapeutic strategies for treatment of cancer. In this review, we briefly discuss the mechanisms by which Ars2 regulates miRNA biogenesis and its impact on cell proliferation and cancer development. Particularly, we mainly discuss the role of Ars2 in the regulation of cancer development and highlight pharmacological targeting of Ars2 as a promising cancer therapeutic strategy.
抗砷蛋白2（Ars2）是一种核蛋白，在微小RNA（miRNA）生物合成的调控中起关键作用。Ars2通过对miRNA加工的可能影响，对细胞增殖和哺乳动物发育的早期阶段是必需的。越来越多的证据表明，Ars2在增殖的癌细胞中高表达，这表明Ars2可能是癌症的一个潜在治疗靶点。因此，开发新型Ars2抑制剂可能代表治疗癌症的新型治疗策略。在这篇综述中，我们简要讨论了Ars2调节miRNA生物合成的机制及其对细胞增殖和癌症发展的影响。特别地，我们主要讨论了Ars2在癌症发展调控中的作用，并强调将Ars2作为一种有前景的癌症治疗策略进行药物靶向治疗。
